The predictive value of single nucleotide polymorhpisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study

Torben Frøstrup Hansen; René dePont Christensen; Rikke Fredslund Andersen; Karen-Lise Garm Spindler; Anders Johnsson; Anders Jakobsen

The predictive value of single nucleotide polymorhpisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study

Torben Frøstrup Hansen, René dePont Christensen, Rikke Fredslund Andersen, Karen-Lise Garm Spindler, Anders Johnsson, Anders Jakobsen

Research output: Contribution to conference without publisher/journal › Poster › Research

Original language	English
Publication date	2011
Publication status	Published - 2011
Event	ASCO Annual Meeting 2011 - Chicago, United States Duration: 3. Jun 2011 → 7. Jun 2011

Conference

Conference	ASCO Annual Meeting 2011
Country/Territory	United States
City	Chicago
Period	03/06/2011 → 07/06/2011

Cite this

Hansen, T. F., Christensen, R. D., Fredslund Andersen, R., Spindler, K.-L. G., Johnsson, A., & Jakobsen, A. (2011). The predictive value of single nucleotide polymorhpisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study. Poster session presented at ASCO Annual Meeting 2011, Chicago, United States.

Hansen, Torben Frøstrup ; Christensen, René dePont ; Fredslund Andersen, Rikke et al. / The predictive value of single nucleotide polymorhpisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study. Poster session presented at ASCO Annual Meeting 2011, Chicago, United States.

@conference{2d457dbcb95743a1948dbf4ce28365ba,

title = "The predictive value of single nucleotide polymorhpisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study",

author = "Hansen, {Torben Fr{\o}strup} and Christensen, {Ren{\'e} dePont} and {Fredslund Andersen}, Rikke and Spindler, {Karen-Lise Garm} and Anders Johnsson and Anders Jakobsen",

year = "2011",

language = "English",

note = "ASCO Annual Meeting 2011 ; Conference date: 03-06-2011 Through 07-06-2011",

}

Hansen, TF, Christensen, RD, Fredslund Andersen, R, Spindler, K-LG, Johnsson, A & Jakobsen, A 2011, 'The predictive value of single nucleotide polymorhpisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study', ASCO Annual Meeting 2011, Chicago, United States, 03/06/2011 - 07/06/2011.

The predictive value of single nucleotide polymorhpisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study. / Hansen, Torben Frøstrup; Christensen, René dePont; Fredslund Andersen, Rikke et al.
2011. Poster session presented at ASCO Annual Meeting 2011, Chicago, United States.

Research output: Contribution to conference without publisher/journal › Poster › Research

TY - CONF

T1 - The predictive value of single nucleotide polymorhpisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study

AU - Hansen, Torben Frøstrup

AU - Christensen, René dePont

AU - Fredslund Andersen, Rikke

AU - Spindler, Karen-Lise Garm

AU - Johnsson, Anders

AU - Jakobsen, Anders

PY - 2011

Y1 - 2011

M3 - Poster

T2 - ASCO Annual Meeting 2011

Y2 - 3 June 2011 through 7 June 2011

ER -

Hansen TF, Christensen RD, Fredslund Andersen R, Spindler KLG, Johnsson A, Jakobsen A. The predictive value of single nucleotide polymorhpisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study. 2011. Poster session presented at ASCO Annual Meeting 2011, Chicago, United States.